[药物与饲管]

[Drugs and feeding tubes].

作者信息

Gorzoni Milton Luiz, Della Torre Anderson, Pires Sueli Luciano

机构信息

Hospital Geriátrico e de Convalescentes Dom Pedro II, Disciplina Fundamentos de Gerontologia do Departamento de Clínica Médica da Faculdade de Ciências Médicas da Santa Casa de São Paulo, S.Paulo, SP.

出版信息

Rev Assoc Med Bras (1992). 2010 Jan-Feb;56(1):17-21. doi: 10.1590/s0104-42302010000100009.

DOI:10.1590/s0104-42302010000100009

PMID:20339780

Abstract

OBJECTIVE

Define the prevalence of drugs that are not compatible with this way of administration for inpatients in long term care facilities (LTCF), and their use in feeding tubes.

METHODS

Analysis of prescriptions for LTCF inpatient who are using feeding tubes for more than 48 hours. The active ingredients, presentation and possibility of pulverizing drugs prescribed were compared to data in literature regarding the feasibility of enteral administration of drugs.

RESULTS

Feeding tubes were observed in 57 patients (11.2% of the total of inpatients), mean age of 65.6 +/- 16.0 years, 32 women and 25 men. Mean number of drugs administered enterally: 5.6 +/- 2.2. Medication items in prescriptions: 316 divided into 64 drugs, with 129 items (40.8% of the total), and 23 drugs (35.4%) inappropriate for such administration. Inappropriate medications most often prescribed were: captopril, phenytoin, ranitidine, omeprazole, and B complex. Alternative presentations were found for 15 (65.2%) of the 23 drugs that were not appropriate for enteral administration

CONCLUSION

Feeding tubes as a way of drug administration for LTCF have a significant risk of including prescriptions which are not compatible.

摘要

目的

确定长期护理机构（LTCF）中与这种给药方式不兼容的药物在住院患者中的流行情况，以及它们在喂食管中的使用情况。

方法

分析使用喂食管超过48小时的LTCF住院患者的处方。将所开药物的活性成分、剂型以及粉碎药物的可能性与文献中关于药物肠内给药可行性的数据进行比较。

结果

观察到57例患者（占住院患者总数的11.2%）使用了喂食管，平均年龄为65.6±16.0岁，其中女性32例，男性25例。肠内给药的平均药物数量：5.6±2.2。处方中的药物项目：316项，分为64种药物，其中129项（占总数的40.8%）和23种药物（占35.4%）不适合这种给药方式。最常开具的不适当药物为：卡托普利、苯妥英、雷尼替丁、奥美拉唑和复合维生素B。对于23种不适合肠内给药的药物，发现有15种（65.2%）有替代剂型。